title: BCL1 lymphoma protection induced by idiotype DNA vaccination is entirely dependent on anti-idiotypic antibodies.
abstract: DNA vaccination with the idiotype (Id) of tumour B-cell membrane immunoglobulins (Ig) is a validated strategy to induce tumour protection to several mouse lymphomas. The relative contribution of anti-Id antibodies and T lymphocytes to tumour rejection is still debated. Previous studies in the BCL1 lymphoma model showed that scFv DNA immunisation induces a polyclonal antibody response restricted to conformational epitopes formed by the parental V(L)/V(H) association. We implemented a system based on this specificity to investigate the mechanism of BCL1 lymphoma protection induced by DNA immunisation. Antibody response and survival of mice immunised with the tumour Id scFv were compared with those of mice immunised simultaneously with two chimeric scFvs, containing either the tumour-derived V(L) or V(H) paired to an irrelevant V(H) or V(L) domain, respectively. Animals vaccinated with one or both chimeric constructs were not protected, despite the exposure to all putative tumour Id-derived MHC class I and class II T-cell epitopes. In addition, conformational antibodies induced by DNA vaccination caused tumour cells apoptosis and cell cycle arrest in vitro and transferred protection in vivo. Therefore, lymphoma rejection appears to be completely dependent on the induction of anti-Id antibodies.
authors.affiliation: International Centre for Genetic Engineering and Biotechnology, Padriciano 99, 34012 Trieste, Italy.
authors.forename: Michela
authors.initials: M
authors.lastname: Cesco-Gaspere
authors.forename: Federica
authors.initials: F
authors.lastname: Benvenuti
authors.forename: Oscar R
authors.initials: OR
authors.lastname: Burrone
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000235:genetics*; D017209:Apoptosis / Q000276:immunology; D002453:Cell Cycle / Q000276:immunology; D019938:Cyclin D1 / Q000235:genetics* / Q000378:metabolism; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D005260:Female; D005805:Genes, MHC Class I / Q000276:immunology; D005802:Genes, MHC Class II / Q000276:immunology; D006801:Humans; D007128:Immunoglobulin Fragments / Q000276:immunology; D007130:Immunoglobulin Idiotypes / Q000276:immunology; D007135:Immunoglobulin Variable Region / Q000276:immunology*; D007167:Immunotherapy; D016393:Lymphoma, B-Cell / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D015996:Survival Rate; D013601:T-Lymphocytes / Q000378:metabolism; D013602:T-Lymphocytes, Cytotoxic; D014611:Vaccination; D019444:Vaccines, DNA / Q000008:administration & dosage*
chemical_list: D000888:Antibodies, Anti-Idiotypic; D018984:Epitopes, T-Lymphocyte; D007128:Immunoglobulin Fragments; D007130:Immunoglobulin Idiotypes; D007135:Immunoglobulin Variable Region; D019444:Vaccines, DNA; D019938:Cyclin D1